Photo by nci from unsplash
Treatment of non‐IgM type I cryoglobulinaemic vasculitis (CV) is challenging. Corticosteroids are first‐line therapy, but relapses are frequent leading to therapeutic escalation. Bortezomib is a proteasome inhibitor with rapid effect… Click to show full abstract
Treatment of non‐IgM type I cryoglobulinaemic vasculitis (CV) is challenging. Corticosteroids are first‐line therapy, but relapses are frequent leading to therapeutic escalation. Bortezomib is a proteasome inhibitor with rapid effect on monoclonal component. However, its use in non‐IgM type I CV has been barely reported.
Keywords:
cryoglobulinaemic vasculitis;
non igm;
type cryoglobulinaemic;
igm type
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!